Découvrez nos professeurs et professeures!

Paul Toren

Médecin clinicien enseignant agrégé

Paul Toren
Centre de recherche sur le cancer
Centre de recherche du CHU de Québec - Université Laval
Partager la fiche :

Contribution à la recherche

Axe de recherche de l'Université Laval :

Santé et bien-être durables

Thématiques de recherche de la Faculté de médecine :

Oncologie

Domaines et intérêts de recherche du (de la) professeur(e) :

Cancer
  • Cancer la prostate
  • Cancer de l'appareil urinaire
  • Cancers hormonaux-dépendants
  • Interaction hôte - tumeur

Projets de recherche

  • Targeting sex steroids to improve the response to bladder cancer immunotherapy - Instituts de recherche en santé du Canada - Subvention Projet, chercheur principal - 2021-10-01 au 2026-09-30
  • Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma - Société de recherche sur le cancer - UpCycle 2.1, co-chercheur - 2022-08-01 au 2026-07-31
  • Exploiter les interactions endocriniennes-immunes pour améliorer le traitement des cancers urologiques - Fonds de recherche du Québec - Santé - Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, chercheur principal - 2022-07-01 au 2024-06-30
  • Food and Drug Regulations_CUASF Bladder Cancer Canada Terms of Reference 2022 - Association canadienne d'urologie, chercheur principal - 2022-08-02 au 2023-08-01
  • A study of macrophages as predictors of prostate cancer radiotherapy response - Association canadienne d'urologie, chercheur principal - 2022-01-26 au 2023-01-25

Publications

  • Canadian Urological Association, 63rd Annual Meeting, Edmonton, AB, June 22-25, 2008., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008
  • The patient presenting with genitourinary AIDS, Wendy Wobeser, Paul Toren, Supportive Care for the Urology Patient, 2005, 10.1093/acprof:oso/9780198529415.003.0017
  • Is 24-hour urinary calcium a surrogate marker for dietary calcium intake?, Norman RW, Toren PJ, Urology, 2005, 10.1016/j.urology.2004.10.025
  • 2012 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012
  • Use of a novel parenchymal clamp for laparoscopic and open partial nephrectomy., McLean A, Jain U, Al-Essawi T, Toren P, Canadian Urological Association Journal, 2010
  • 2010 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010
  • Comparison of epidural and intravenous patient controlled analgesia in patients undergoing radical cystectomy., Fleshner N, McCluskey S, Ma C, Ladak S, Toren P, The Canadian journal of urology, 2009
  • Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer, Martin E Gleave, Paul J Toren, Asian Journal of Andrology, 2013, 10.1038/aja.2013.38
  • Re: Shilo Y, Zisman A, Lindner A, et al. The predominance of benign histology in small testicular masses. Urol Oncol 2012;30:719-22., Lo K, Toren P, Urologic oncology, 2013, 10.1016/j.urolonc.2012.11.018
  • Diet, Obesity, and Cancer Progression: Are Adipocytes the Link?, Vasundara Venkateswaran, Benjamin C. Mora, Paul Toren, Lipid Insights, 2013, 10.4137/lpi.s10871
  • Catastrophic sepsis and hemorrhage following transrectal ultrasound guided prostate biopsies, John Trachtenberg, Roshan Razik, Paul Toren, Canadian Urological Association Journal, 2013, 10.5489/cuaj.785
  • Results of a national population-based study of outcomes of surgery for renal tumors associated with inferior vena cava thrombus., Finelli A, Alibhai S, Kulkarni G, Timilshina N, Abouassaly R, Toren P, Urology, 2013, 10.1016/j.urology.2013.04.054
  • Periprostatic Adipose Tissue and Prostate Cancer Progression: New Insights into the Tumor Microenvironment, Vasundara Venkateswaran, Paul Toren, Clinical Genitourinary Cancer, 2014, 10.1016/j.clgc.2013.07.013
  • Active surveillance in patients with a PSA >10 ng/mL, Antonio Finelli, Neil Fleshner, John Trachtenberg, Shabbir Alibhai, Narhari Timilshina, Lih-Ming Wong, Paul Toren, Canadian Urological Association Journal, 2014, 10.5489/cuaj.2121
  • Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT., Crook JM, Gospodarowicz M, Goldenberg L, Malone S, Horwitz E, Higano CS, Dearnaley D, Toren P, Ding K, O'Callaghan C, Klotz L, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, 10.1200/jco.2014.58.2973
  • Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models., Zoubeidi A, Gleave ME, Fazli L, Davies BR, Crafter C, Cordonnier T, Kim S, Toren P, European urology, 2015, 10.1016/j.eururo.2014.08.006
  • Sex steroids in the tumor microenvironment and prostate cancer progression, Paul Toren, Clovis Boibessot, Endocrine-Related Cancer, 2018, 10.1530/erc-17-0493
  • Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer, Amina Zoubeidi, Fraser Johnson, Soojin Kim, Paul Toren, PLOS ONE, 2016, 10.1371/journal.pone.0152861
  • Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low‐risk prostate cancer receiving 5α‐reductase inhibitors, Yves Fradet, Thierry Dujardin, Rabi Tiguert, Frédéric Pouliot, Louis Lacombe, Tal Ben‐Zvi, Alain Bergeron, André Caron, Caroline Léger, Jérome Lévesque, Michele Lodde, Molière Nguile‐Makao, Paul Toren, Vincent Fradet, BJU International, 2018, 10.1111/bju.14041
  • Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?, Paul Toren, Yves Fradet, Michele Lodde, Vincent Fradet, Louis Lacombe, Catherine McMartin, Clinical Genitourinary Cancer, 2019, 10.1016/j.clgc.2019.07.016
  • Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients, Paul Toren, Caroline Gilbert, Yves Fradet, Frédéric Pouliot, Hon Sing Leong, Fannie Morin, Mélanie Rouleau, Fabrice Lucien, France‐Hélène Joncas, The Prostate, 2019, 10.1002/pros.23901
  • CYCLOPHOSPHAMIDE INDUCED HEMORRHAGIC CYSTITIS SUCCESSFULLY TREATED WITH PENTOSANPOLYSULPHATE, RICHARD W. NORMAN, PAUL J. TOREN, The Journal of Urology, 2005, 10.1097/01.ju.0000146626.78180.83
  • Circulating Basophils as a Prognostic Marker for Response to Bacillus Calmette-Guérin, Paul Toren, Peter C. Black, Jonathan Fadel, Typhaine Gris, Raphaëlla Rosebush-Mercier, Timo Nykopp, Geneviève Trépanier, Clinical Genitourinary Cancer, 2023, 10.1016/j.clgc.2023.12.004
  • The effect of nerve-sparing surgery on patient-reported continence post-radical prostatectomy., Trachtenberg J, Fleshner N, Kalnin R, Nesbitt M, Matthew A, Alibhai SM, Toren P, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: A randomized study., Ritvo P, Trachtenberg J, Matthew AG, Guglietti C, Toren P, Alibhai SM, Connor MK, Santa Mina D, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2013, 10.5489/cuaj.235
  • Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?, Toren P, Klotz L, Current oncology (Toronto, Ont.), 2012, 10.3747/co.19.1298
  • Small incidentally discovered testicular masses in infertile men--is active surveillance the new standard of care?, Lo KC, Jarvi K, Grober ED, Lecker I, Roberts M, Toren PJ, The Journal of urology, 2010, 10.1016/j.juro.2009.12.012
  • Rational cotargeting of Pim-1 and Akt in prostate cancer, Amina Zoubeidi, Paul Toren, Expert Review of Anticancer Therapy, 2013, 10.1586/14737140.2013.816461
  • Use of a novel parenchymal clamp for laparoscopic and open partial nephrectomy, Umesh Jain, Anthony Mclean, Turki Al-Essawi, Paul Toren, Canadian Urological Association Journal, 2013, 10.5489/cuaj.936
  • Effects of omega‐3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double‐blind placebo‐controlled randomized trial, Vincent Fradet, Karine Robitaille, Yves Fradet, Michele Lodde, Frédéric Pouliot, Paul Toren, Thierry Dujardin, Yves Caumartin, Rabi Tiguert, Louis Lacombe, Pierre Julien, Jean‐François Pelletier, Hanane Moussa, Josée Savard, Cancer Medicine, 2023, 10.1002/cam4.6598
  • Supplementary Figures 1-3, Supplementary Tables 1-5 from Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial, Laurence Klotz, Chantal Guillemette, Éric Lévesque, Yves Fradet, Frédéric Pouliot, Patrick Caron, Véronique Turcotte, France-Hélène Joncas, Keyue Ding, Azik Hoffman, Paul Toren, 2023, 10.1158/1078-0432.22475735.v1
  • Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy, Vincent Fradet, Karine Robitaille, Yves Fradet, Rabi Tiguert, Thierry Dujardin, Michele Lodde, Paul Toren, Louis Lacombe, Narcisse Singbo, Jean-François Pelletier, Samuel Fradet, Clinical Nutrition ESPEN, 2022, 10.1016/j.clnesp.2021.12.011
  • Switching Cancers: A Systematic Review Assessing the Role of Androgen Suppressive Therapy in Bladder Cancer, Paul Toren, Richard T. Bryan, Alexandre Zlotta, Michele Lodde, Catherine McMartin, Kassim Kourbanhoussen, European Urology Focus, 2021, 10.1016/j.euf.2020.10.002
  • Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival, Yves Fradet, Alain Bergeron, Louis Lacombe, Hélène Hovington, David Simonyan, Hervé Brisson, Paul Toren, World Journal of Urology, 2021, 10.1007/s00345-020-03358-x
  • Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial, Laurence Klotz, Chantal Guillemette, Éric Lévesque, Yves Fradet, Frédéric Pouliot, Patrick Caron, Véronique Turcotte, France-Hélène Joncas, Keyue Ding, Azik Hoffman, Paul Toren, Clinical Cancer Research, 2018, 10.1158/1078-0432.CCR-18-1187
  • Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer, Paul Toren, Louis Lacombe, Yves Fradet, Anne-Sophie Julien, Sarah-Jeanne Cyr, Joanie Pelletier, Urologic Oncology: Seminars and Original Investigations, 2018, 10.1016/j.urolonc.2018.05.004
  • MP62-06 COMBINED AKT AND MEK PATHWAY BLOCKADE IN PRE-CLINICAL MODELS OF ENZALUTAMIDE-RESISTANT PROSTATE CANCER, Amina Zoubeidi, Soojin Kim, Paul Toren, The Journal of Urology, 2016, 10.1016/j.juro.2016.02.914
  • Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review), AMINA ZOUBEIDI, PAUL TOREN, International Journal of Oncology, 2014, 10.3892/ijo.2014.2601
  • Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer., Zoubeidi A, Bishop JL, Cox ME, Gust KM, Lamoureux F, Fazli L, Beraldi E, Vahid S, Toren P, Thaper D, Nip KM, Zardan A, Oncogenesis, 2014, 10.1038/oncsis.2014.30
  • 2015 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015
  • 236 EXPERIENCE WITH RECTOURETHRAL FISTULA REPAIR AND DESCRIPTION OF A NOVEL SURGICAL TECHNIQUE, Sender Herschorn, Paul Toren, Ashley Cox, The Journal of Urology, 2012, 10.1016/j.juro.2012.02.291
  • Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (eCancerCareBladder): a randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records., Jewett MA, Grober ED, Fleshner NE, Finelli A, Zlotta AR, Chagpar A, Legere L, Lane K, Liu J, Truong T, Chow R, Xi H, Toren PJ, Bostrom PJ, Journal of the American Medical Informatics Association : JAMIA, 2011, 10.1136/amiajnl-2011-000221
  • PD32-01 PRE-CLINICAL RATIONALE FOR COMBINATION PI3K AND BRD4 INHIBITION IN ADVANCED PROSTATE CANCER, Amina Zoubeidi, Soojin Kim, Jared Allman, Paul Toren, The Journal of Urology, 2016, 10.1016/j.juro.2016.02.677
  • Catastrophic sepsis and hemorrhage following transrectal ultrasound guided prostate biopsies., Trachtenberg J, Razik R, Toren P, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010
  • 2009 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • Data from Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial, Laurence Klotz, Chantal Guillemette, Éric Lévesque, Yves Fradet, Frédéric Pouliot, Patrick Caron, Véronique Turcotte, France-Hélène Joncas, Keyue Ding, Azik Hoffman, Paul Toren, 2023, 10.1158/1078-0432.c.6529157
  • Supplementary Figures 1-3, Supplementary Tables 1-5 from Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial, Laurence Klotz, Chantal Guillemette, Éric Lévesque, Yves Fradet, Frédéric Pouliot, Patrick Caron, Véronique Turcotte, France-Hélène Joncas, Keyue Ding, Azik Hoffman, Paul Toren, 2023, 10.1158/1078-0432.22475735
  • Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer, Paul Toren, Laurence Klotz, Keyue Ding, Juanita M. Crook, Frédéric Pouliot, Lily Summers-Trasiewicz, Samuel Tremblay, Journal of Urology, 2021, 10.1097/JU.0000000000001946
  • Reply by Authors, Paul Toren, Laurence Klotz, Keyue Ding, Juanita M. Crook, Frédéric Pouliot, Lily Summers-Trasiewicz, Samuel Tremblay, Journal of Urology, 2021, 10.1097/JU.0000000000001946.03
  • Switching from a GnRH agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysis, Paul Toren, Neil Fleshner, Christopher J.D. Wallis, Kaleem S. Atchia, Canadian Urological Association Journal, 2019, 10.5489/cuaj.5996
  • 2017 NSAUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4896
  • Analysis of the translatome in solid tumors using polyribosome profiling/RNA-Seq, Rachid Mazroui, Paul Toren, Edouard W. Khandjian, Arnaud Droit, Valerie Grenier St-Sauveur, Pauline Adjibade, Journal of Biological Methods, 2016, 10.14440/jbm.2016.151
  • Pre-clinical rationale for combination PI3K and BRD4 inhibition in advanced prostate cancer., Jared Allman, Amina Zoubeidi, Paul Toren, Journal of Clinical Oncology, 2016, 10.1200/jco.2016.34.2_suppl.234
  • Podium Session 1: Prostate Cancer June 26, 2016 1050–1150., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2016
  • Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer., Gleave ME, Moore W, Zoubeidi A, Guns ES, Adomat H, Mangalji A, Pham S, Kim S, Toren PJ, Molecular cancer therapeutics, 2015, 10.1158/1535-7163.mct-14-0521
  • Novel non-AR therapeutic targets in castrate resistant prostate cancer., Gleave ME, Toren PJ, Translational andrology and urology, 2013, 10.3978/j.issn.2223-4683.2013.09.09
  • Reply, Antonio Finelli, Paul Toren, Urology, 2013, 10.1016/j.urology.2013.04.056
  • Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study., Fleshner N, Zlotta A, Finelli A, Kulkarni G, Margel D, Toren P, BMJ (Clinical research ed.), 2013, 10.1136/bmj.f2109
  • Data from Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial, Laurence Klotz, Chantal Guillemette, Éric Lévesque, Yves Fradet, Frédéric Pouliot, Patrick Caron, Véronique Turcotte, France-Hélène Joncas, Keyue Ding, Azik Hoffman, Paul Toren, 2023, 10.1158/1078-0432.c.6529157.v1
  • The sex gap in bladder cancer survival — a missing link in bladder cancer care?, Richard T. Bryan, Ananya Choudhury, Taha Lodhi, Roger Kockelbergh, Typhaine Gris, Amy Burley, Keval Patel, Anna Wilkins, Paul Toren, Nature Reviews Urology, 2023, 10.1038/s41585-023-00806-2

Contribution à l'enseignement aux cycles supérieurs

Étudiant(e)s dirigé(e)s*

Depuis 2009
  • Geneviève Trépanier - Maîtrise avec mémoire - En cours
  • Heidi Shore - Maîtrise avec mémoire - En cours
  • Samuel Tremblay - Maîtrise avec mémoire - En cours

Encadrement d'étudiant(e)s pour les programmes suivants :

Disponibilité d'encadrement d'étudiant(e)s

Ce (cette) professeur(e) est présentement à la recherche d'étudiant(e)s.

Envoyer un courriel
*Les supervisions d’étudiant(e)s de 1er cycle en stage de recherche et de résident(e)s aux études médicales postdoctorales seront répertoriées ultérieurement.